RESEARCH ARTICLE

ASSOCIATION BETWEEN GAMMA GLUTAMYL TRANSFERASE AND METABOLIC SYNDROME IN YOUNG ADULTS IN EASTERN INDIA: AN OBSERVATIONAL STUDY

Dan Subhasish[1], Aditya Papia[2], *Banerjee Prithwijit[3], Rahaman Musfikur[4],Roy Himansu[5], Adak Shiuli Roy[6], Jana Tamoghna[7].

1. MD. Demonstrator, Department of Biochemistry, Medical College Kolkata.
2. M Sc, Assistant Teacher, Tejganj High School, Burdwan.
3. MD. Demonstrator, Department of Pharmacology, Medical College Kolkata.
4. MD. Assistant Professor, Department of Pharmacology, Medical College Kolkata
5. MD. Associate Professor, Department of General Surgery, Medical College, Kolkata.
6. MD. Associate Professor, Department of Biochemistry, North Bengal Medical College, Darjeeling.
7. MBBS, DLO, Post graduate trainee, Department of ENT, Medical College Kolkata.

Corresponding Author's e-mail: drprithwijit@gmail.com, Contact no: +91-9830500513

ABSTRACT

Introduction: Alanine aminotransferase (ALT), Aspartate aminotransferase (AST), Gamma glutamyl transferase (GGT) are the principal hepatic enzymes in clinical laboratory setup. ALT and AST are elevated in various types of hepatitis, cirrhosis and hepatic neoplasia. GGT is usually elevated in alcoholism. Recently, in some studies, the elevation of GGT has been observed in metabolic syndrome. **Objective:** To study the relationship of gamma glutamyl transferase (GGT) with Metabolic Syndrome (MS) in a population. **Materials and Methods:** 91 MS patients and 94 age and sex matched control individuals were recruited into the study, after obtaining their voluntary informed consent. Serum GGT levels along with other biochemical parameters of all the participants were compared statistically **Results:** Serum GGT level was significantly higher in MS group than in non MS group (p = 0.007).**Conclusion:** MS contributed towards higher GGT level in our study population.

Key words: Metabolic Syndrome (MS), Gamma glutamyltransferase (GGT), Alanine aminotransferase (ALT), Aspartate aminotransferase (AST).

INTRODUCTION:

HTN, obesity, dyslipidemia are often various symptoms of a metabolic disorder called Metabolic Syndrome (MS).Various bodies have defined metabolic syndrome based on biochemical parameters and clinical examination. According to *National Cholesterol Education Programme – Adult Treatment Plan III* (NCEP ATP III)[1], presence of any three of the followings make the diagnosis of metabolic syndrome.

Abdominal obesity (Waist circumference)

Men >102 cm (>40 inch)

Women >88 cm (>35 inch)

Triglycerides >150 mg/dL

HDL cholesterol

Men < 40 mg/dL

Women < 50 mg/dL

Blood pressure >130/>85 mmHg

Fasting glucose >110 mg/dL

International Diabetes Federation (IDF) has defined metabolic syndrome by presence of:

Central obesity (defined as waist circumference ≥ 90cm for South Asian men and ≥ 80cm for South Asian women, with ethnicity specific values for other groups)

Plus any two of the following four factors:

• **Raised TG level:** ≥ 150 mg/dL (1.7 mmol/L), or **specific treatment for this lipid abnormality**

•**Reduced HDL cholesterol**: < 40 mg/dL (1.03 mmol/L) in males and < 50 mg/dL (1.29 mmol/L) in females, **or specific treatment for this lipid abnormality**

• **Raised blood pressure:** systolic BP ≥ 130 or diastolic BP ≥ 85 mm Hg, **or treatment of previously diagnosed hypertension**

• **Raised fasting plasma glucose** (FPG) ≥ 100 mg/dL (5.6 mmol/L), **or previously diagnosed type 2 diabetes**

As per the IDF Consensus Worldwide Definition of the Metabolic Syndrome, both IR and central obesity are considered the principal factors responsible for clustering of the pentad of CVD risk factors in MS. As per NCEP-ATP III, overweight and obesity are associated with insulin resistance and the metabolic syndrome. However, the presence of abdominal obesity is more highly correlated with the metabolic risk factors than is an elevated body mass index (BMI).

An estimated 47 million U.S. residents have the metabolic syndrome[2]. Epidemiological studies have recorded a high prevalence of metabolic syndrome[3, 4, 5] and cardiovascular mortality[6, 7, 8] among Indians, including those settled outside of India.

Gamma Glutamyl Transferase (GGT) is an enzyme which is used as a marker of alcohol intake and

subsequent hepatic injury. Cellular GGT is widely distributed in human body and is usually localized to the plasma membrane with its active site directed into the extracellular space[9]. The highest activity of GGT is found in kidney, on the luminal surface of proximal tubular cells. Interestingly, although serum GGT is known as one of the liver enzymes, cellular GGT activity in homogenates of liver is approximately one-fifth that in kidney. Principal role of GGT is to breakdown extracellular reduced GSH, allowing the precursor amino acids to be assimilated into cell and reutilized for intracellular GSH synthesis.

Essential hypertension is often associated with insulin resistance (IR). 25-50 % of non-obese, non-diabetic patients with EHTN have IR[1].

In some studies, a significant association was found between serum GGT level and prehypertension[10] (SBP 130-139 and/or DBP 80-89) and hypertension[11]. Furthermore, GGT level has been found to be good predictor of susceptibility to type II diabetes mellitus[12,13] and hypertension[8]. Considering these atypical features of GGT and keeping in mind that the above-mentioned studies have been carried out in people of different ethnicity, there is a perceived need to verify if the association between GGT and MS holds for eastern Indian population too.

MATERIALS AND METHODS

The study samples were collected from the OPD of Clinical Biochemistry Laboratory at the Department of Biochemistry, Medical College, Kolkata. The study subjects included both male and female MS patients and age and sex matched non MS individuals in the age group of 18-35 years.

The study period spanned from December 2011 to March 2012.

Total 185 patients were enrolled into the study. Of them, 91 had MS and 94 were controlled individuals. The applied selection criteria were as follows:

Inclusion Criteria

Patients of either sex aged 18 to 35 years and diagnosed with metabolic syndrome on the basis of NCEP ATP III criteria with age and sex matched controls, who attended the OPDs during the study period and gave their voluntary written informed consent for the study.

Exclusion Criteria

- Pregnant and lactating mothers.
- If the patient is suffering from any of the following conditions:

1. Renal Disease
2. Liver Disease
3. Cardiac Disease
4. Active Infection
5. Any malignancy
6. Known alcoholic patients.

Study Protocol: Sample Collection, Analysis

Before collection of data or blood sample, each patient was explained the details of the study including rationale, expected benefits, risk profile, confidentiality safeguards and study protocol. For some patients, help of appropriate interpreter(s) was taken. Only those patients who were willing to follow the study protocol and gave their written consent were included in the study. There was neither any financial cost nor any financial incentive for the patient for being part of the study.

1. Appropriate blood samples were collected from MS patients and age and sex matched non MS individuals. For estimation of serum GGT, cholesterol, triglyceride, HDL and plasma glucose fasting blood sample were drawn into serum (without anticoagulant) gel containing yellow colour capped BD Vacutainer tubes. All samples were immediately centrifuged and stored at 2-8°C until analysis for the relevant biochemical parameters. All analyses were performed within 3 hours of sample collection.

2. Serum Cholesterol was measured by XL600 autoanalyzer using CHOD-PAP principle.

3. Serum Triglyceride was measured by XL600 autoanalyzer using Glycerol Kinase principle.

4. Serum HDL was measured by ERBA Chem 5 V2 semi-autoanalyzer using PEG Precipitation principle.

5. Serum GGT level was measured by XL600 autoanalyzer using Gamma Glutamyl p-Nitroanilidine (GPNA) principle.

6. Plasma glucose was measured by XL600 autoanalyzer using GOD-POD principle.

7. Serum Albumin was measured by XL600 autoanalyzer using BCG principle.

8. Serum total protein was measured by XL600 autoanalyzer using Biuret principle.

9. Patients' recent-most blood/plasma/serum values of the afore-mentioned biochemical parameters were noted, if already available, provided they were done on the same day.

Patients' relevant anthropometric data were collected. The serum levels of GGT, Cholesterol, Triglyceride, HDL and fasting plasma glucose levels of the two groups were compared for presence or absence of statistically significant differences.

Statistical Analysis

The statistical software R version 2.11.1 was used to analyze the data. All values were expressed as mean $\pm$ standard deviation unless otherwise indicated, and differences in mean values between two groups were analysed using Student's t-test (Table 1). Descriptive information regarding categorical variable were presented as frequency. Fischer's exact probability test was used for comparison of categorical data. All tests were two tailed and considered statistically significant if p-value < level of significance, 0.05.

RESULTS

The present study confirms the finding of earlier studies that serum GGT level in MS patients is higher than their non MS counterparts (p=0.007). There were no significant differences in age, serum albumin, serum total protein between the two groups. Serum levels of cholesterol, triglyceride, HDL and fasting plasma glucose levels were significantly different in two groups. Systolic blood pressure was also found to be higher among the MS group, which stood statistically significant.

Table 1: The biochemical parameters of MS and non MS groups

	Control Group	MS Group	p-value
Number of patients	94	91	
Male/Female	56/38	50/41	0.62
Age (years)	27.02 ± 6.78	26.81 ± 7.81	0.177
SBP (mmHg)	126 ± 12	130 ± 16	0.006*
DBP (mmHg)	79 ± 9	81 ± 8	0.262
Waist Circumference (cm)	79 ± 8	89 ± 10	0.033*
Total Protein (g/dL)	7.1 ± 0.5	6.9 ± 0.6	0.082
Albumin (g/dL)	5.1 ± 0.6	4.9 ± 0.5	0.083
Cholesterol (mg/dL)	177 ± 56	211 ± 62	0.331
Triglyceride (mg/dL)	129 ± 39	169 ± 48	0.048*
Fasting Plasma Glucose (mg/dL)	86 ± 12	92 ± 15	0.033*
HDL (mg/dL)	46 ± 8	39 ± 6	0.006*
Gamma glutamyltransferase (U/L)	43.7 ± 51.7	61.8 ± 68.2	0.007*

* p<0.05 is considered to be statistically significant

DISCUSSION

Our study confirms the empirical validity of the observation made in earlier studies that serum GGT level is higher in metabolic syndrome patients compared to age and sex matched normal individuals.

GGT has hitherto been used as a marker of alcohol consumption[14]. In earlier studies, it had been shown that correlation between GGT and hypertension is independent of alcohol intake[15]. A similar significant association had been found among non-drinkers[16] too. However, another study, taking the contribution of insulin level in determining GGT level, had established a non-significant correlation between GGT level and hypertension but a significant correlation between GGT level and plasma insulin level[17]. Further credence has been lent to the hypothesis that plasma insulin level is the principal determinant of GGT in metabolic syndrome patients and hypertensives[18].

A mechanism has been put forward to account for the pathological role of insulin in elevation of GGT. Elevated insulin level may lead to hepatic steatosis[19,20,21], and subsequently, Non Alcoholic Fatty Liver Disease (NAFLD). Steatosis appears when insulin secretion is sufficient to block free fatty acid oxidation but not sufficient to block free fatty acid mobilization from adipose tissue[22]. Free fatty acids are markedly cytotoxic and may cause alteration in hepatic cell membrane function and leakage of GGT[23].

GGT is also known to act as an antioxidant by virtue of its central role in GSH cycle. Hypertension being a state of high oxidative stress, elevated GGT level can be explained as a compensatory mechanism[24].

Furthermore, recent studies have revealed a pro-oxidant generating[25,26,27,28] role of GGT. GGT generates ROS in presence of free iron or other transition metal. These authors suggested that the GGT mediated generation of the more reactive thiol cysteinyl- glycine could cause the reduction of ferric iron Fe(III) to ferrous Fe(II), thus starting a redox- cycling process liable to result in the production of reactive oxygen species (ROS). Considering that insulin stimulates ferritin synthesis[29,30,31] and hypertension is a hyperinsulinemic state, it is more likely than not that hypertensive individuals have higher ferritin level. In vitro experimental studies have reported that free iron can be released from iron storage proteins such as ferritin by superoxide radicals or nitric oxide[32,33,34]. It is well known that substantial oxidative stress exists in diabetes[35,36] and hypertension[37,38]. Therefore, patients with diabetes or hypertension might have a potential to have free iron released from iron storage protein, and in this case, cellular GGT might act as a pro-oxidant.

CONCLUSION

The results of this population-based cross-sectional study suggest that GGT may serve as a marker for metabolic syndrome. It should be borne in mind in the clinical practice that elevated levels of GGT may not always indicate increased alcohol consumption, but may simply suggest the existence of metabolic syndrome with its subsequent deleterious consequences viz. type II diabetes mellitus, hypertension and carotid atherosclerosis.

Conflict of interest: There was nothing to best of our knowledge.

REFERENCES:

1 NCEP ATP III Guidelines At-A-Glance Quick Desk Reference

2 Ford, ES, et al. Prevalence of the metabolic syndrome among US adults: findings from the Third National Health and Examination Survey. JAMA 2002;287:356–9.

3 McKeigue PM, Pierpoint T, Ferrie JE, Marmot MG. Relationship of glucose intolerance and hyperinsulinaemia to body fat pattern in south Asians and Europeans. Diabetologia 1992; 35 : 785-91.

4 Misra A, Vikram NK. Insulin resistance syndrome (metabolic syndrome) and Asian Indians. Curr Sci 2002; 83 : 1483-7.

5 Deepa R, Shanthirani CS, Premalatha G, Sastry NG, Mohan V. Prevalence of insulin resistance syndrome in a selected south Indian population - the Chennai urban population study-7 (CUPS-7). Indian J Med Res 2002; 115: 118-27.

6 Kamath SK, Hussain EA, Amin D, Mortillaro E, West B, Peterson CT, et al. Cardiovascular disease risk factors in 2 distinct ethnic groups: Indian and Pakistani compared with American premenopausal women. Am J Clin Nutr 1999; 69: 621-31.

7 McKeigue PM, Ferrie JE, Pierpoint T, Marmot MG. Association of early-onset coronary heart disease in South Asian men with glucose intolerance and hyperinsulinemia. Circulation 1993; 87 : 152-61.

8 Enas EA, Garg A, Davidson MA, Nair VM, Huet BA, Yusuf S. Coronary heart disease and its risk factors in first generation immigrant Asian Indians to the United States of America. Indian Heart J 1996; 48: 343-53.

9 Hanigan MH, Frierson HF. Immunohistochemical detection of gamma glutamyl transpeptidase in normal human tissue. J Histochem Cytochem 1996; 44:1101–8.

10 Shankar A, Li J. Association between serum gamma glutamyl transferase level and prehypertension among US adults. Circ. J. 2007; 71:1567-71.

11 Lee D H, Ha M H, Kim J R, Gross M, Jacobs D R. Gamma glutamyltrandferase, alcohol and blood pressure : A four year follow-up study. Ann Epidemiol. 2002; 12:90-96.

12 Perry IJ, Wannamethee SG, Shaper AG. Prospective study of serum gamma-glutamyltransferase and risk of NIDDM. Diabetes Care 1998; 21: 732-7.

13 Duk-Hee Lee, David R. Jacobs, Jr., Myron Gross, Catarina I. Kiefe. Jeffrey Roseman, Cora E. Lewis, Michael Steffes. Gamma glutamyltransferase Is a predictor of Incident diabetes and hypertension: The Coronary Artery Risk Development in Young Adults (CARDIA) Study. Clinical Chemistry 2003; 49(8):1358–1366.

14 Wannamethee G, Ebrahim S, Shaper AG. Gamma-glutamyltransferase: determinants and association with mortality from ischemic heart disease and all causes. Am J Epidemiol 1995; 142: 699-708.

15 Yamada Y, Ishizaki M, Kido T, Honda R, Tsuritani I, Nogawa K, Yamaya H. Relationship between serum gamma-glutamyl transpeptidase activity, blood pressure and alcohol consumption. J Hum Hypertens 1989; 3: 409-17.

16 Yamada Y, Ishizaki M, Kido T, Honda R, Tsuritani I, Ikai E, Yamaya H. Alcohol, high blood pressure, and serum gglutamyl transpeptidase level. Hypertension 1991; 18: 819-26.

17 Ikai E, Ishizaki M, Suzuki Y, Ishida M, Noborizaka Y, Yamada Y. Association between hepatic steatosis, insulin resistance and hyperinsulinaemia as related to hypertension in alcohol consumers and obese people. J Hum Hypertens 1995; 9: 101-5.

18 Koutis AD, Lionis CD, Isacsson AÊ , Jakobsson A, Fioretos M, Lindholm. LH. Characteristics of the `Metabolic Syndrome X' in a cardiovascular low risk population in Crete. Eur Heart J 1992; 13: 865-71.

19 Nomura F, Ohnishi K, Satomura Y, Ohtsuki T, Fukunaga K, Honda M, et al. Liver function in moderate obesity study in 534 moderately obese subjects among 4613 male company employees. Int J Obesity 1986; 10: 349-54.

20 Wanless IR, Bargman JM, Oreopoulos DG, Vas SI. Subcapsular steatonecrosis in response to peritoneal insulin delivery: a clue to the pathogenesis of steatonecrosis in obesity. Modern Pathol 1989; 2: 69-74.

21 Fagerberg B, Lindstedt G, Berglund G. Effects of alcohol intake and obesity on serum liver enzyme activity in obese men with mild hypertension. J Intern Med 1993; 233: 477-84.

22 Wanless IR, Bargman JM, Oreopoulos DG, Vas SI. Subcapsular steatonecrosis in response to peritoneal insulin delivery: a clue to the pathogenesis of steatonecrosis in obesity. Modern Pathol 1989; 2: 69-74.

23 Wenzel DG, Hale TW. Toxicity of free fatty acids for cultured rat heart muscle and endothelial cells. Toxicol 1978; 11: 109.

24 Ceriello A, Motz E. Is oxidative stress the pathogenic mechanism underlying insulin resistance, diabetes, and cardiovascular disease? The common soil hypothesis revisited. Arterioscler Thromb Vasc Biol 2004 ;24: 816–823.

25 Stark AA. Oxidative metabolism of glutathione by gamma-glutamyl transpeptidase and peroxisome proliferation: the relevance to hepatocarcinogenesis. A hypothesis. Mutagenesis 1991;6:241–5.

26 Stark AA, Russell JJ, Langenbach R, Pagano DA, Zeiger E, Huberman E. Localization of oxidative damage by a glutathione-gamma-glutamyl transpeptidase system in preneoplastic lesions in sections of livers from carcinogen-treated rats. Carcinogenesis 1994; 15:343–8.

27 Paolicchi A, Tongiani R, Tonarelli P, Comporti M, Pompella A. Gamma-Glutamyl transpeptidase-dependent lipid peroxidation in isolated hepatocytes and HepG2 hepatoma cells. Free Radic Biol Med 1997;22:853–60.

28 Drozdz R, Parmentier C, Hachad H, Leroy P, Siest G, Wellman M. Gamma-Glutamyltransferase dependent generation of reactive oxygen species from a glutathione/transferrin system. Free Radic Biol Med 1998;25:786–92.

29 Davis RJ, Corvera S, Czech MP. Insulin stimulates cellular iron uptake and causes the redistribution of intracellular transferrin receptors to the plasma membrane. J Biol Chem 261:8708–8711, 1986.

30 Yokomori N, Iwasa Y, Aida K, Inoue M, Tawata M, Onaya T. Transcriptional regulation of ferritin messenger ribonucleic levels by insulin in cultured rat glioma cells. Endocrinology 128:1474–1480, 1991.

31 Tanner LI, Lienhard GE. Localization of transferrin receptors and insulinlike growth factor II receptors in vesicles from 3T3–L1 adipocytes that contain intracellular glucose transporters. J Cell Biol1989; 108:1537–1545.

32 Biemond P, van Eijk HG, Swaak AJ, Koster JF. Iron mobilization from ferritin by superoxide derived from stimulated polymorphonuclear leukocytes. Possible mechanism in inflammation diseases. J Clin Invest 1984;73:1576–9.

33 Reif DW, Simmons RD. Nitric oxide mediates iron release from ferritin. Arch Biochem Biophys 1990;283:537–41.

34 Comporti M, Signorini C, Buonocore G, Ciccoli L. Iron release, oxidative stress and erythrocyte ageing. Free Radic Biol Med 2002;32:568–76.

35 Wilson JG, Lindquist JH, Grambow SC, Crook ED, Maher JF. Potential role of increased iron stores in diabetes. Am J Med Sci 2003;325:332–9.

36 Fernandez-Real JM, Lopez-Bermejo A, Ricart W. Cross-talk between iron metabolism and diabetes. Diabetes 2002;51:2348–54.

37 Portaluppi F, Boari B, Manfredini R. Oxidative stress in essential hypertension. Curr Pharm Des 2004;10:1695–8.

38 Hamilton C. Nitric oxide, oxidative stress and hypertension: a complex equation. J Hypertens 2002; 20:1055–6.